Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Third Quarter 2011 Results Announcement)
Reporting Period: Three and nine months ended 30 September 2011
Issuance Date: 26 October 2011
GSK reported strong third-quarter performance driven by underlying sales growth across Pharmaceuticals, Vaccines, and Consumer Healthcare. The company continues to execute a strategy focused on growing a diversified global business, delivering products of value, and simplifying its operating model. Key strategic activities include the divestment of non-core OTC brands and a major restructuring program targeting £2.5 billion in savings by the end of 2012.
Key Financial Metrics
| Metric | Q3 2011 | Q3 2010 | 9 Months 2011 | 9 Months 2010 |
|---|---|---|---|---|
| Turnover (£m) | 7,104 | 6,813 | 20,409 | 21,195 |
| Operating Profit (£m) (Before major restructuring) |
2,179 | 2,129 | 6,318 | 5,165 |
| Operating Profit (£m) (Total) |
2,115 | 1,958 | 5,928 | 4,103 |
| Earnings Per Share (p) (Before major restructuring) |
28.5p | 28.2p | 85.8p | 61.5p |
| Earnings Per Share (p) (Total) |
27.6p | 25.3p | 79.4p | 45.7p |
| Adjusted Net Cash Inflow (£m) (Operating Activities) |
2,318 | 1,964 | 5,358 | 6,646 |
| Net Debt (£m) (As of 30 Sep 2011) |
9,497 | — | — | — |
Note: Cash flow figures for Q3 2010 are derived from the text description of adjusted net cash inflow trends where specific Q3 2010 totals were not explicitly tabulated in the summary section, though 9-month comparisons are provided.
Material Changes vs. Prior Period
- Sales Growth: Reported turnover increased 3% in Q3 2011, while underlying sales (excluding pandemic products, Avandia, and Valtrex) grew 6%. For the nine months, reported sales declined 3% due to the loss of high-margin pandemic products, but underlying sales grew 5%.
- Profitability: Operating profit before major restructuring grew 3% in Q3 and 24% in the nine months. The nine-month increase was driven by lower legal charges and R&D costs, partially offset by the decline in sales of pandemic-related products.
- Geographic Performance:
- Japan: Strong growth (+57% underlying in Q3) driven by the Cervarix HPV vaccine rollout.
- Emerging Markets: Underlying sales growth of 11% in Q3.
- Europe: Decline of 4% in underlying sales due to austerity price cuts.
- USA: Underlying sales growth of 1% in Q3.
- Divisional Performance:
- Vaccines: Underlying sales up 21% in Q3, led by Cervarix, Synflorix, and Rotarix.
- Pharmaceuticals: Underlying sales up 2% in Q3.
- Consumer Healthcare: Underlying sales up 5% in Q3, led by Oral care (+10%) and Nutrition (+9%).
Guidance, Outlook, and Risks
- Shareholder Returns:
- Dividend: Third interim dividend increased 6% to 17p per share.
- Buybacks: 2011 share repurchase expectations increased to up to £2.3 billion (from £2.0 billion).
- Operational Outlook:
- Full-year operating margin guidance (excluding legal and other operating income) remains unchanged, expected to be around one percentage point lower than 2010.
- Restructuring program is on track to deliver £2.5 billion in savings by end of 2012.
- Full-year impact of US Healthcare Reform and European price cuts expected to be approximately £325 million.
- R&D Pipeline:
- 6 of 15 assets with Phase III data expected by end of 2012 have reported data.
- Key developments: Data received on malaria vaccine (RTS,S), IPX066 (Parkinson's), and Promacta (Hepatitis C). One study (otelixizumab) failed to show efficacy.
- Risks and Contingencies:
- Legal: Aggregate provision for legal and other disputes is £2.9 billion. Significant proceedings include product liability and intellectual property disputes (e.g., Teva Pharmaceuticals regarding Epzicom).
- Taxation: Effective tax rate for the nine months was 29.6%. Full-year rate expected to be around 29.5% excluding tax on proposed Consumer Healthcare divestments.
- Divestment: Bidding process for non-core OTC brands is ongoing, with a target conclusion by year-end.
Investor Verification Checklist
- Underlying vs. Reported Sales: Verify the impact of excluding pandemic products, Avandia, and Valtrex on reported growth figures.
- Japan Vaccine Rollout: Assess the sustainability of the Cervarix sales surge in Japan following the national HPV program rollout.
- Legal Provisions: Review the £2.9 billion legal provision and potential exposure from the Teva Epzicom litigation and other product liability cases.
- OTC Divestment: Monitor the progress and valuation of the non-core OTC brand divestment process.
- Pension Deficit: Note the increase in the pension deficit to £2.214 billion due to lower discount rates and asset value decreases.
- Share Buyback Execution: Confirm the execution of the increased £2.3 billion share repurchase program for 2011.